Though bevirimat had particular challenges, in that people who had resistance to protease inhibitors were less likely to benefit from the drug, the company said it had at least one backup compound if bevirimat proved ineffective.
It is unclear whether Myriad will sell these compounds to another company for further development.
Myriad had been developing a maturation inhibitor called bevirimat (MPC-4326, PA-457) since 2009, after purchasing the rights to the drug from Panacos Pharmaceuticals
New 52wkhi, something going on http://stockcharts.com/c-sc/sc?s=PANC&p=d&b=1&g=1&id=p17970548896
Looking further.....
sc
Pro Traders Forum http://investorshub.advfn.com/boards/board.aspx?board_id=18631
Track New Vol_Alerts http://investorshub.advfn.com/boards/board.aspx?board_id=21832
**Trade Well Trade Often**
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM